Cohen Veterans Bioscience (CVB), a nonprofit research organization dedicated to fast-tracking personalized diagnostics and therapeutics for brain health, today announced its strategic collaboration with Parexel Biotech, a new division of Parexel, for CVB’s adaptive platform trial evaluating pharmacotherapeutics to treat posttraumatic stress disorder (PTSD). Cohen Veterans Bioscience would like to honor our military veterans by highlighting the ways we are transforming science to advance brain health.RECENT NEWS
GET UPDATES
We Need Precision Medicine for The Brain
We bring together the brightest minds and deploy the most innovative scientific tools with an emphasis on scale, risk-minimization, efficiency and speed.
Recent Highlights
News
Cohen Veterans Bioscience and Parexel Biotech Collaborate on Landmark Adaptive Platform Trial Studying Posttraumatic Stress Disorder (PTSD) Pharmacotherapeutics
Events
Driving Progress on Veterans Brain Health
Home
